Brain Advance Access originally published online on March 14, 2006
Brain 2006 129(5):1249-1259; doi:10.1093/brain/awl061
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Apoptosis in mitochondrial myopathies is linked to mitochondrial proliferation
1 Institut National de la Santé et de la Recherche Médicale, U582, 2 Université Pierre et Marie Curie, 3 AP HP, CHU Pitié-Salpêtrière, Institut de Myologie, Paris, 4 AP HP, Hôpital Ambroise Paré, Physiologie, Boulogne-Billancourt, 5 UFR Médicale Paris-Ile-de-France-Ouest and 6 Hôpital Morvan, Service d'Anatomo-pathologie, Brest, France
Correspondence to: Anne Lombès, Inserm U582, Institut de Myologie, Groupe hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris Cedex, France E-mail: a.lombes{at}myologie.chups.jussieu.fr
Increased susceptibility to apoptosis has been shown in many models of mitochondrial defects but its relevance to human diseases is still discussed. We addressed the presence of apoptosis in muscle from patients with mitochondrial DNA (mtDNA) disorders. Taking advantage of the mosaic pattern of muscle morphological anomalies associated with heteroplasmic mtDNA alterations, we have used an in situ approach to address the relationship between apoptosis and respiratory defect, mitochondrial proliferation and mutation load. Different patterns of mitochondrial morphological alterations were provided by the analysis of muscles with large mtDNA deletion (16 cases) or with the MELAS mutation (4 cases). The patient's age at biopsy ranged from 0.4 to 66 years and the muscle mutant mtDNA proportion from 32 to 82%. Apoptotic muscle fibres were observed in a small proportion of muscle fibres of 16 out of the 20 biopsies by three different detection methods for different steps of apoptosis: caspase 3 activation, fragmentation of nuclear DNA [terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay] or overexpression of the pro-apoptotic factor Bax. Analysis of apoptotic features in parallel to cytochrome c oxidase (COX) and succinate dehydrogenase activity of more than 34 000 individual muscle fibres showed that apoptosis occurred only in muscle fibres with mitochondrial proliferation (ragged red fibres, RRF) irrespective of their COX activity. Molecular analyses of single muscle fibres evidenced that, as expected, the presence of COX defect was associated with higher proportion of mutant mtDNA and lower amount of normal mtDNA. Within COX-defective fibres, the presence of mitochondrial proliferation was associated with increase of the mtDNA content but without change in the ratio between normal and mutant mtDNA molecules, thus showing that mitochondrial proliferation was accompanied by similar amplification of normal and mutant mtDNA molecules. Within RRF, apoptosis was associated with higher mutation proportion, suggesting that it was provoked by severe respiratory defect in the same time as increased mitochondrial mass. In conclusion, apoptosis most probably contributes to mitochondrial pathology. It is tightly linked to mitochondrial proliferation and high mutation load. When considering training therapeutics, one will have to take into account the possibility to induce apoptosis in parallel to mitochondrial proliferation.
Key Words: apoptosis; mitochondrial myopathies; mitochondrial DNA; deletion
Abbreviations: COX = cytochrome c oxidase; MELAS = mitochondrial encephalopathy with lactic acidosis and stroke-like episodes; mtDNA = mitochondrial DNA; PBS = phosphate-buffered saline; RRF = ragged red fibres; SDH = succinate dehydrogenase; TUNEL = terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling
.
Received September 19, 2005. Revised February 10, 2006. Accepted February 19, 2006.
* These authors contributed equally to this work.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R G E van Eijsden, L M T Eijssen, P J Lindsey, C M M van den Burg, L E A de Wit, M E Rubio-Gozalbo, C E M de Die, T Ayoubi, W Sluiter, I F M de Coo, et al. Termination of damaged protein repair defines the occurrence of symptoms in carriers of the m.3243A>G tRNALeu mutation J. Med. Genet., August 1, 2008; 45(8): 525 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Kim, C. Jardel, C. Barthelemy, V. Jan, J. P. Bastard, S. Fillaut-Chapin, S. Houry, J. Capeau, and A. Lombes Mitochondrial DNA Content, an Inaccurate Biomarker of Mitochondrial Alteration in Human Immunodeficiency Virus-Related Lipodystrophy Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Aure, H. Ogier de Baulny, P. Laforet, C. Jardel, B. Eymard, and A. Lombes Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement: can we predict progression? Brain, June 1, 2007; 130(6): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Madamanchi and M. S. Runge Mitochondrial Dysfunction in Atherosclerosis Circ. Res., March 2, 2007; 100(4): 460 - 473. [Abstract] [Full Text] [PDF]
|
|